Financial Statements/ESG Information - [Interim/Half-Year Report]

3D Medicines Inc. operates as a commercial-stage biopharmaceutical company. The Company focuses on the development of differentiated immuno-oncology drugs. 3D Medicines conducts businesses in China.

Interim Report 2025

Announcements and Notices - [Interim Results]

Interim Results Announcement
For The Six Months Ended June 30, 2025

Announcements and Notices - [Other - Business Update]

Voluntary Announcement Successfully Administers First Dose In Human For Novel Radioactive Drug Conjugate 3d1015

Voluntary Announcement
3d Medicines And Catug Biotechnology Join Forces
To Advance Tlnp-Delivered In Vivo Car-T/Nk
Therapy Development

Announcements and Notices - [Date of Board Meeting]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

3D Medicines (1244 HK)

Interim Report 2025

Interim Results Announcement For The Six Months Ended June 30, 2025

Voluntary Announcement Successfully Administers First Dose In Human For Novel Radioactive Drug Conjugate 3d1015

Voluntary Announcement 3d Medicines And Catug Biotechnology Join Forces To Advance Tlnp-Delivered In Vivo Car-T/Nk Therapy Development

Date Of Board Meeting

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)